MiR-125a and miR-125b are two common reported critical genes in human physiological and pathological process especially for regulating inflammation, immune activities, and coagulation. [7] [8] [9] For instance, miR-125a and miR-125b induce inflammation and impair antiviral response via repressing A20 and mitochondrial antiviral signaling (MAVS) in chronic obstructive pulmonary disease (COPD) 8 ; miR-125a and miR-125b promote coagulation via regulating coagulation factor Ⅸ mini-gene through inhibiting nonsense-mediated mRNA decay in mammalian cells. 9 Combining these above data and that the sepsis is featured by severe inflammation, dysregulated immune activities, and coagulation, we hypothesized that miR-125a and miR-125b might possess the potential to be biomarker for sepsis.
Thus in this present study, we aimed to investigate the correlation of miR-125a/b expressions with sepsis risk, and further explore their association with disease progression and prognosis in sepsis patients.
| MATERIAL S AND ME THODS

| Participants
Between January 2016 and May 2018, 120 sepsis patients and 
| Data collection
When the written informed consents were obtained from patients or their guardians, clinical characteristics of all enrolled sepsis were recorded, such as age, gender, body mass index (BMI) smoke, chronic comorbidities including chronic obstructive pulmonary disease (COPD), cardiomyopathy, chronic kidney failure and cirrhosis, serum creatinine (Scr), albumin, white blood cell (WBC), C-reactive protein (CRP), and procalcitonin (PCT). Besides, acute physiology and chronic health evaluation (APACHE) II score as well as sequential organ failure assessment (SOFA) score assessed within 24 hours after ICU admission were also collected, which were used to evaluate disease severity (higher scores were associated with higher severity). All enrolled sepsis patients were treated in accordance with the guidelines and followed up until mortality in the hospital or discharge, and the number of survivors and non-survivors were recorded.
| Blood samples collection
For the enrolled sepsis patients, blood samples were collected within 24 hours after ICU admission; as for the HCs, blood samples were collected after they signed informed consents. All samples were centrifuged to separate plasma within 1 hour after collection at 4°C 2000 g for 10 minutes, then the plasma was scored at −80°C for the further detections of miR-125a/b and inflammatory cytokines.
| Determination of miR-125a/b
Total RNA was extracted from plasma samples using Trizol Reagent 
| Determination of inflammatory cytokines
For the sepsis patients, the levels of inflammatory cytokines including tumor necrosis factor (TNF-α), interleukin-1β (lL-1β), IL-6, and IL-17 in plasma were determined using human enzyme-linked immunosorbent assay (ELISA) kits (Abcam), and all samples processing and operations were carried out in accordance with the kits instructions strictly. 
| Statistical analysis
| RE SULTS
| Characteristics
The mean age of sepsis patients was 59.1 ± 12.1 years, and there were 84 (70.0%) males and 36 (30.0%) females. Nineteen (15.8%), 42 (35.0%), 11 (9.2%), and 21 (17.5%) cases were complicated with COPD, cardiomyopathy, chronic kidney failure, and cirrhosis, respectively. The mean APACHE II score and SOFA score were 15.4 ± 6.4 and 7.2 ± 3.5, respectively. The other detailed characteristics were presented in Table 1 .
| Expressions of miR-125a/b in sepsis patients and HCs
MiR-125a expression showed no difference between sepsis patients and HCs (P = .126) ( Figure 1A ), and ROC curve exhibited miR-125a could not differentiate sepsis patients from HCs with AUC 0.557 95%CI 0.483-0.632 ( Figure 1B) . Interestingly, miR-125b expression was greatly elevated in sepsis patients compared with HCs (P < .001) ( Figure 1C ), and ROC curve revealed that miR-125b could well distinguish sepsis patients from HCs with AUC 0.658 95%CI 0.588-0.728, and the sensitivity and specificity were 49.2% and 80.0% at the best cutoff point which was defined as the point achieved maximum sensitivity plus specificity ( Figure 1D ). In addition, a positive correlation between miR-125a and miR-125b was observed both in sepsis patients (P < .001) ( Figure 1E ) and HCs (P < .001) ( Figure 1F ).
| Correlation of miR-125a/b expressions with APACHE II and SOFA scores in sepsis patients
Correlation of miR-125a/b expressions with general disease severity scores including APACHE II and SOFA was analyzed, which showed that miR-125a was not correlated with APACHE II score (P = .269) ( Figure 2A ) or SOFA score (P = .579) ( Figure 2B ), while miR-125b was positively associated with APACHE II score (P = .003) ( Figure 2C ) and SOFA score (P = .028) ( Figure 2D ).
| Correlation of miR-125a/b expressions with other characteristics in sepsis patients
Correlation of miR-125a/b expressions with other characteristics other than APACHE II and SOFA scores was further analyzed, which illuminated that miR-125a was positively correlated with cardiomyopathy complication (P = .015), and miR-125b was positively correlated with Scr (P = .002), CRP (P < .001), PCT (P = .010), TNF-α (P = .008), and IL-6 (P = .028) levels (Tables 2   and 3 ).
| Correlation of miR-125a/b expressions with mortality in sepsis patients
There were 81 survivors and 39 non-survivors in sepsis patients.
MiR-125a expression showed no difference between survivors and non-survivors (P = .293) ( Figure 3A ), and ROC curve exhibited miR-125a could not differentiate survivors from non-survivors with AUC 0.560 95%CI 0.444-0.675 ( Figure 3B ). Importantly, miR-125b expression was observed to be greatly decreased in survivors compared with non-survivors (P < .001) ( Figure 3C ), and ROC curve revealed that miR-125b could well distinguish survivors from non-survivors with AUC 0.689 95%CI 0.586-0.793, and the sensitivity and specificity were 63.0% and 69.2% at the best cutoff point ( Figure 3D ).
| Factors predicting mortality in sepsis patients
Univariate and multivariate logistic regression model analysis was further performed to explore factors predicting mortality in sepsis Note: Data were presented as mean value ± standard deviation, count (percentage), or median (25th-75th quantiles). Abbreviations: APACHE, acute physiology and chronic health evaluation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; PCT, procalcitonin; Scr, serum creatinine; SOFA, sequential organ failure assessment; TNF, tumor necrosis factor; IL: interleukin; WBC, white blood cell.
patients (Table 4 ). Univariate analysis disclosed that miR-125b expression (P = .001), Scr level (P = .005), CRP level (P < .001), APACHE II score (P = .005), SOFA score (P < .001), TNF-α level (P = .028), IL-1β level (P = .050), and IL-17 level (P = .018) predicted higher risk of mortality.
And further multivariate analysis revealed that miR-125b expression (P = .045), Scr level (P = .050), CRP level (P = .045), and SOFA score (P = .003) were independent factors predicting higher risk of mortality.
| D ISCUSS I ON
In this present study, we observed that: (a) miR-125b was upregulated and positively correlated with APACHE II score, SOFA score, Scr level, and inflammation level in sepsis patients; (b) miR-125b was decreased in survivors compared with non-survivors, and it was an independent factor predicting higher risk of mortality in sepsis patients; (c) miR-125a lacks potential to be marker for disease risk, progression or prognosis in sepsis patients.
Several published studies have revealed that miR-125a and miR-125b might serve as biomarkers for risk for several inflammatory diseases. [11] [12] [13] For example, a recent miRNA sequencing study exhibits that plasma miR-125a and miR-125b are potential markers for increased risk of acute ischemic stroke. 11 Another study revealed that colonic mucosal miR-125b is specially upregulated in ulcerative colitis patients compared with Crohn's disease and HCs, which could serve as a specific marker for ulcerative colitis risk. 12 In addition, plasma miR-125b but not miR-125a was upregulated and correlated with higher risk of acute exacerbation in COPD patients. 13 These studies suggest that miR-125b presents with good potential for serving as biomarker for disease risk of several inflammatory diseases, while miR-125a lacks sufficient evidences. In our study, we observed that miR-125b but not miR-125a was upregulated in sepsis patients compared with HCs, and ROC curve revealed that miR-125b could serve as biomarker for increased risk of sepsis. These might be resulted from that (a) miR-125b promoted inflammatory cells and mediators via transition, and acute-on-chronic liver failure, thus sepsis patients who were characterized as multi-organ dysfunction or failure presented with increased level of miR-125b. 15, 16 It's also reported that miR-125a and miR-125b might be used as biomarker for disease progression or disease severity monitoring, 
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and correlate with systemic inflammation in some diseases. 13, 17, 18 For instance, plasma miR-125a is observed to be negatively correlated with Crohn's disease activity index, CRP level, TNF-α level, and IL-17 level in patients with active Crohn's disease. 13 And plasma exosomal miR-125b is disclosed to be increased in acute-phase ischemic stroke patients compared with subacute-phase ischemic stroke patients. 18 Furthermore, plasma miR-125b is exhibited to be positively correlated with TNF-α level, IL-8 level, and leukotriene B4 level in patients with acute exacerbation of COPD, and miR-125b is gradually decreased after treatment, while miR-125a is not associated with inflammation and does not change after treatment. 13 These studies imply miR-125b correlates with advanced disease progression or severity, as well as elevated inflammation in several inflammatory diseases. In this study, we discovered that miR-125b was positively correlated with APACHE II score, SOFA score, Scr level, and inflammation level in sepsis patients, while miR-125a showed no correlation with disease severity scores/indexes or inflammation.
The possible explanations were that miR-125b promoted inflammation and organ dysfunction (or failures) via various ways as aforementioned studies, [14] [15] [16] downregulation of miR-125b predicts poor response to therapy and short leukemia-free survival and overall survival in pediatric acute lymphoblastic leukemia patients. 20 In this present study, we found that miR-125b but not miR-125a was decreased in survivors compared with non-survivors, and it was an independent factor predicting higher risk of mortality in sepsis patients. These might be due to that miR-125b closely positively correlated with disease severity and inflammation, which resulted in worse outcomes in sepsis patients;
while miR-125a lacked correlation with disease severity scores/indexes or inflammation, thus failed to predict the mortality. Besides, we also explored other independent factors predicting risk of mortality in sepsis patients, and observed that apart from miR-125b, Scr, CRP level, and SOFA score correlates with increased mortality risk as well. These might result from that increased Scr represented severe renal injury, CRP represented enhanced inflammation, and SOFA reflected comprehensive multiple organ failures, thus they independently predicted increased mortality risk.
Several limitations still existed in this present study. Firstly, the sample size was relatively small; Secondly, the correlation of miR-125a/b expression with long-term outcomes was not evaluated;
Thirdly, the molecular mechanism of miR-125a/b in sepsis was not explored.
In conclusion, miR-125b but not miR-125a is upregulated and exhibits a trend to correlate with enhanced disease severity, inflammation, and increased mortality in sepsis patients.
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